SERM Breast Cancer "Prevention" Is Subclinical Disease Therapy - ASCO
Executive Summary
The breast cancer "prevention" effect of the selective estrogen receptor modifiers tamoxifen (Zeneca's Nolvadex) and raloxifene (Lilly's Evista) may be due to treatment of subclinical disease, discussant Kent Osborne, MD, University of Texas, told the American Society of Clinical Oncology May 18 in Los Angeles.